Travers Smith LLP has advised the senior management team of Essential Pharma, a global specialty pharmaceutical business focused on ensuring that patients have access to clinically differentiated, niche, branded pharmaceutical products, on the completion of a €900 million recapitalisation through a Gyrus Capital single-asset Continuation Vehicle led by AlpInvest, and a new strategic financing facility with Sixth Street.
The transaction provides Essential Pharma with significant resources to build on its diversified portfolio and late-stage pipeline across established and rare disease medicines. The additional capital will further support Essential Pharma’s mission to ensure access to essential medicines for patients.
The Travers Smith team was led by Private Equity & Financial Sponsors Partner Alex Dixon, with support from Senior Associate Jaryd Davidson, Associate Matthew Hoyle and Trainee Solicitor Liam Carrington. Tax advice was provided by Partner Hannah Manning supported by Associate Ross McGregor.
